Search Results - "Hsiao, Hsiu‐ling"

Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol by Hsiao, Hsiu-ling, Langenickel, Thomas Heiko, Greeley, Michael, Roberts, John, Zhou, Wei, Pal, Parasar, Rebello, Sam, Rajman, Iris, Sunkara, Gangadhar

“…LCZ696 is a first‐in‐class angiotensin receptor neprilysin inhibitor in development for treatments of hypertension and heart failure indications. In 3 separate…”
Get full text

Role of intestinal P-glycoprotein ( ) in interpatient variation in the oral bioavailability of cyclosporine by Lown, Kenneth S., Mayo, Robert R., Leichtman, Alan B., Hsiao, Hsiu‐ling, Turgeon, D. Kim, Schmiedlin‐Ren, Phyllissa, Brown, Morton B., Guo, Wensheng, Rossi, Stephen J., Benet, Leslie Z., Watkins, Paul B.

“…Interpatient differences in the oral clearance of cyclosporine (INN, ciclosporin) have been partially attributed to variation in the activity of a single liver…”
Get full text

Pharmacokinetics of Dapoxetine Hydrochloride in Healthy Chinese, Japanese, and Caucasian Men by Thyssen, An, Sharma, Om, Tianmei, Si, Aquilina, Joseph W., Vandebosch, An, Wang, Shean-Sheng, Mudumbi, Ramagopal, Hsiao, Hsiu-Ling

“…Dapoxetine is a short‐acting selective serotonin reuptake inhibitor developed for the on‐demand treatment of premature ejaculation and is approved in some…”
Get full text

Abstract 457: Assessment of Pharmacokinetic Drug-drug Interaction between LCZ696 and Carvedilol by Hsiao, Hsiu-Ling, Greeley, Michael, Pal, Parasar, Langenickel, Thomas, Sunkara, Gangadhar, Chandra, Priyamvada

“…Abstract only Objective: LCZ696 is a first-in-class angiotensin receptor neprlysin inhibitor (ARNI) being developed for the treatment of hypertension and heart…”
Get full text

Abstract 455: Assessment of Pharmacokinetic Drug-drug Interaction between LCZ696 and Hydrochlorothiazide by Hsiao, Hsiu-Ling, Greeley, Michael, Pal, Parasar, Langenickel, Thomas, Sunkara, Gangadhar, Chandra, Priyamvada

“…Abstract only Objective: LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) being developed for the treatment of cardiovascular…”
Get full text